Recently, a CD4-based CAR that was re-engineered (see details below) to incorporate lessons learned from successful cancer targeting CARs (6), was shown to confer greater antiviral activity than widely-investigated broadly neutralizing antibody (BNAb) based CARs. Here, CD4 is linked to cancer.